<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024163</url>
  </required_header>
  <id_info>
    <org_study_id>LPRI747-301</org_study_id>
    <nct_id>NCT04024163</nct_id>
  </id_info>
  <brief_title>Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease</brief_title>
  <official_title>Prospective, Single-arm, Multicentre Study, Using a Historical Control, to Evaluate the Efficacy/Safety and Population Pharmacokinetics of Benznidazole in Children With Chronic Indeterminate Chagas Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insud Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chemo Research S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Insud Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the efficacy and safety of benznidazole in the treatment of chronic
      indeterminate Chagas disease in children. All subjects will receive benznidazole and results
      will be compared to historically to a placebo arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2019</start_date>
  <completion_date type="Anticipated">March 2, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Historical control-based comparison, single-arm assignment, multicentre study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serological Cure by Conventional ELISA</measure>
    <time_frame>72-month follow up</time_frame>
    <description>Percentage of patients with negative conventional ELISA results as a measure of serological cure at the end of the 72-month follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serological Cure by Conventional ELISA at different timepoints</measure>
    <time_frame>Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up</time_frame>
    <description>Percentage of patients with negative conventional ELISA results as a measure of serological cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological Cure by two conventional serology tests at 72 month</measure>
    <time_frame>72 months of follow-up</time_frame>
    <description>Percentage of patients with two negative conventional serology results as a measure of serological cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological Cure by two conventional serology tests at 48 months</measure>
    <time_frame>48 months of follow-up</time_frame>
    <description>Percentage of patients with two negative conventional serology results as a measure of serological cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological Cure by three serology tests at different timepoints</measure>
    <time_frame>Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up</time_frame>
    <description>Percentage of patients with three negative serology results as a measure of serological cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological Cure by Non-Conventional ELISA at different timepoints</measure>
    <time_frame>Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up</time_frame>
    <description>Percentage of patients with negative non-conventional ELISA (F29) results as a measure of serological cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure by qPCR at different timepoints</measure>
    <time_frame>Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up</time_frame>
    <description>Consistently negative quantitative polymerase chain reaction (qPCR) results as a surrogate measure of cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological titres reduction at different timepoints</measure>
    <time_frame>Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up</time_frame>
    <description>Reduction of conventional and nonconventional serological titres over the period of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of clinical disease at different timepoints</measure>
    <time_frame>Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up</time_frame>
    <description>Percentage of patients with progression to clinical disease over the period of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of clinical disease and serological cure by one assay at different timepoints</measure>
    <time_frame>48 and 72 months of follow-up</time_frame>
    <description>Percentage of patients with no evidence of established cardiomyopathy over the period of follow-up and seroconversion to negative by one assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of clinical disease and serological cure by two assays at different timepoints</measure>
    <time_frame>48 and 72 months of follow-up</time_frame>
    <description>Percentage of patients with no evidence of established cardiomyopathy over the period of follow-up and seroconversion to negative by two assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Day 60 (EOT), and 4, 6, 12, 24, 36, 48, 60, and 72 months of follow-up</time_frame>
    <description>Rate and severity of adverse events (AEs)</description>
  </other_outcome>
  <other_outcome>
    <measure>Population Pharmacokinetic - blood concentration</measure>
    <time_frame>pre-dose, day 7 and day 30</time_frame>
    <description>Benznidazole blood concentrations</description>
  </other_outcome>
  <other_outcome>
    <measure>Population Pharmacokinetic - area under the curve (AUC)</measure>
    <time_frame>pre-dose, day 7 and day 30</time_frame>
    <description>Benznidazole area under the curve (AUC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Population Pharmacokinetic - volume of distribution</measure>
    <time_frame>pre-dose, day 7 and day 30</time_frame>
    <description>Benznidazole volume of distribution</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensive Pharmacokinetic - blood concentrations</measure>
    <time_frame>Day 1 or day 7</time_frame>
    <description>Benznidazole blood concentrations</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensive Pharmacokinetic - area under the curve (AUC)</measure>
    <time_frame>Day 1 or day 7</time_frame>
    <description>Benznidazole area under the curve (AUC)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Chagas Disease</condition>
  <arm_group>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benznidazole 100 mg Tablets or Benznidazole 12.5 mg Tablets by mouth, every 12 hours for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benznidazole</intervention_name>
    <description>Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <other_name>National Drug Code (NDC) 0642-7464-10</other_name>
    <other_name>National Drug Code (NDC) 0642-7464-12</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 2 years and 18 years (age limits inclusive)

          -  Diagnosis of Trypanosoma cruzi (T. cruzi) infection by conventional serology based on
             positive ELISA and at least 1 other positive conventional serology test (recombinant
             ELISA or IIF)

          -  Written informed consent by parent/legal representative and informed assent from
             patients if &gt;7 years old when applicable (as requirements may vary by country and by
             site)

          -  Females of childbearing potential (ie, female patients who have experienced menarche)
             and male patients must agree to use highly effective contraception if sexually active
             from the time of signing of the informed consent/assent form until â‰¥5 days after the
             last dose of study treatment

        Exclusion Criteria:

          -  Pregnant or intending to become pregnant during treatment and within 5 days after the
             last dose of study treatment

          -  Patient presenting any other acute or chronic health conditions, which in the opinion
             of the Principal Investigator (PI), may interfere with the pharmacokinetic (PK),
             efficacy, and/or safety evaluation of the study treatment

          -  Signs and/or symptoms of acute Chagas Disease

          -  Known history of hypersensitivity or serious adverse reactions to nitroimidazoles

          -  History of Chagas Disease treatment with Benznidazole (BZN) or nifurtimox

          -  Immunocompromised (clinical history compatible with human immunodeficiency virus (HIV)
             infection, primary immunodeficiency, or prolonged treatment with corticosteroids or
             other immunosuppressive drugs)

          -  Abnormal laboratory test values (as per protocol-specified ranges) at Screening for
             the following parameters: total white blood cell (WBC) count, platelet count, alanine
             aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and
             creatinine

          -  Abnormal ECG (as per protocol-specified ranges) and/or any Chagas disease associated
             findings

          -  Any condition that prevents the patient from taking oral medication

          -  Patient is known to or suspected of not being able to comply with the study protocol
             and the use of the investigational medicinal product (IMP)

          -  Evidence or history of alcohol or drug abuse (within the last 12 months)

          -  Any planned procedure that may interfere with highly effective contraception during
             treatment and within 5 days after the last dose of study treatment

          -  Employee of the Investigator or trial centre, or family member of the employees or the
             Investigator

          -  Any condition that, in the opinion of the Investigator, may jeopardise the trial
             conduct according to the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enrico Colli, MD</last_name>
    <phone>0034-913-021-560</phone>
    <email>enrico.colli@exeltis.com</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzonidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

